Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Citigroup Inc (C) Top Kahn Brothers’ Portfolio

Page 1 of 2

Kahn Brothers Advisors LLC is an Investment Advisor company providing brokerage and money management services to clients. An old member of the NY Stock Exchange, Kahn Brothers was founded in 1978 as Kahn Brothers & Company, Inc. The fund primarily invests in companies which are unpopular and undervalued. Co-founder and former chairman Irving Kahn (pictured), who recently passed away at the age of 109 started his career in the 1930’s and studied under Benjamin Graham, who also counted Warren Buffett as one of his proteges. The total value of the equity portfolio of Kahn Brothers stood at $592.07 million as of March 31. In this article we will take a look at four companies: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Citigroup Inc (NYSE:C), and International Business Machines Corp. (NYSE:IBM), which rank as major holdings  in the portfolio of Kahn Brothers.

Irving Kahn

Kahn Brothers is just one of more than 700 hedge funds that we track in our database, whose equity portfolios we collate quarterly as part of our small-cap strategy. Even though most smaller investors believe that tracking 13F filings is a fruitless endeavor because they are filed with a delay of a maximum of 45 days after the end of a calendar quarter, the results of our research prove that is not the case. To be on the safe side, we used a delay of 60 days in our backtests that involved the 13F filings of funds between 1999 and 2012 and we still managed to gain an annual alpha in the double digits. Moreover, since the official launch of our strategy in August 2012, our small-cap strategy has obtained returns of more than 137%, beating the S&P 500 Total Return Index by 82 percentage points (see the details).

On the top spot in Kahn Brothers’ portfolio is is Pfizer Inc. (NYSE:PFE), in which the fund owns 1.81 million shares valued at $63.01 million. Pfizer Inc. is a pharmaceutical corporation headquartered in New York. The company produces and researches vaccines and drugs. Pfizer Inc. (NYSE:PFE), one of the most profitable companies in the world, had first quarter earnings of $0.51 per share on revenue of $10.9 billion. It also bought back $6.0 billion worth of common stock during the quarter. During the first quarter Pfizer’s new products enjoyed strong sales and it continued to push growth by announcing the purchase of Hospira, Inc. Pfizer Inc. (NYSE:PFE) continues to advance its products and is well-positioned in new domains of biology. During the remainder of 2015 it will continue to focus on its key products such as Viagra, Xeljanz, Prevnar 13, Eliquis and Nexium 24HR, which helped fuel its recent revenue growth. Billionaire Ken Fisher has the largest holding of Pfizer in our database at 31.21 million shares.

In second position is Merck & Co. Inc (NYSE:MRK), in which Kahn Brothers holds 1.03 million shares with a value of $59.19 million. During the first quarter Merck posted earnings were $0.33 per share with revenue coming in at $9.4 billion, a decrease of 8% compared with the first quarter of 2014. Merck experienced positive sales growth in a number of key segments including the animal health domain, oncology, hospital acute care, vaccines, drugs, diabetes, while it suffered a sales decline in hepatitis C. In the first quarter the company was focused on important launches of new products Keytruda, Belsomra, and Zerbaxa. At current exchange rates  Merck & Co. Inc continues to anticipate full year 2015 profit to be between $38 billion and $40 billion. The most significant hedge fund holdings in Merck & Co. Inc are held by AQR Capital Management and billionaire Fisher.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!